store at low temperature
store at -80°C
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 355.00 | |
5 mg | In stock | $ 928.00 | |
10 mg | In stock | $ 1,490.00 |
Description | Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC). |
Targets&IC50 | EGFR:0.22 nM (Kd), LGR5:0.85 nM (Kd) |
In vitro | Treatment with MCLA-158(Petosemtamab) (1 µg/mL; 24 or 72 hours) induces the degradation of EGFR in EGFR+/LGR5+ colorectal cancer organoids[2]. |
In vivo | Treatment with MCLA-158(Petosemtamab) (25 mg/kg/week, intravenous injection, for 6 weeks) leads to tumor regression in esophageal squamous cell carcinoma, gastric adenocarcinoma, and head and neck PDX models[2]. |
Synonyms | MCLA 158 |
Molecular Weight | N/A |
CAS No. | 2213450-26-9 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Petosemtamab 2213450-26-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR MCLA 158 MCLA158 MCLA-158 inhibitor inhibit